Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220154 · ClinicalTrials.gov registry record · Phase 1
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
A Phase 1 study, sponsored by David O'Malley.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01220154 is a Phase 1 study that has completed, run by David O'Malley. The registered enrollment target is 9 participants.
The verdict
NCT01220154, a Phase 1 study, has completed, sponsored by David O'Malley.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with advanced ovarian carcinoma.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-04-28 |
| Est. Completion | 2023-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220154
The ClinicalTrials.gov registry entry for NCT01220154 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David O'Malley, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01220154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220154 about?
NCT01220154 is a clinical study titled "Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer". Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with advanced ovarian carcinoma.
What is the current status of trial NCT01220154?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2011-04-28. Estimated completion is 2023-07-17.
What interventions are being tested in trial NCT01220154?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01220154?
This trial is sponsored by David O'Malley, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.